Johnson & Johnson (J&J) MedTech has introduced the MENTOR MemoryGel Enhance Breast Implants in the US, aiming to address a significant need in breast cancer care for women post-mastectomy.
These implants are specifically designed for women with larger breasts and represent the first of their kind in terms of size, ranging from 930 cc to 1445 cc, allowing surgeons to achieve personalised results without aesthetic compromise.
The introduction of these implants addresses the needs of approximately 15% of women who undergo mastectomy and previously lacked access to appropriately sized reconstruction options.
With breast cancer cases on the rise, over 246,000 women opt for mastectomy annually as part of their treatment or prevention strategy. Reconstruction with implants provides these women with the opportunity to restore form and volume after surgery.
Prior to this launch, the largest available implant was 800 cc, which often resulted in challenges achieving proportionality for patients with larger body frames or those requiring extensive tissue removal. This limitation frequently led to issues with symmetry, suboptimal aesthetic outcomes, or necessitated additional surgeries.
Johnson & Johnson MedTech aesthetics and reconstruction worldwide president Alenka Brzulja said: “Johnson & Johnson MedTech is delivering on our promise to make breast reconstruction more inclusive, supportive, and empowering for every woman.
“Too many women have been left without options that helped them achieve their desired outcomes. The availability of MemoryGel Enhance Implants brings us closer to addressing this gap – because every woman deserves access to reconstruction options that reflect her body and her goals.”
The MemoryGel Enhance Implants retain the proprietary gel formulation known for softness and shape retention found in the existing MENTOR portfolio.
Now available in a wider range of sizes, encompassing various base widths, projections, and volumes, these implants better cater to diverse patient needs.
The MENTOR Enhance Product Family includes MemoryGel Enhance Implants, CPX4 Plus Enhance Breast Tissue Expanders, and MemoryGel Enhance Breast Implant Sizers to provide a complete reconstruction solution.
Approved by the US Food and Drug Administration (FDA) in November 2024 for both primary and revision reconstruction, these implants’ safety and effectiveness were verified through three-year data from the Athena Study.
This study is noted as the largest multicentre, prospective 10-year clinical trial focused on breast implants for reconstruction. It showed a 96% overall patient satisfaction rate alongside low complication incidences and marked improvements in physical, psychosocial, and sexual well-being.
